Modelling dysplasia detection in ulcerative colitis: Clinical implications of surveillance intensity

Gut

Volumn 58, Issue 11, 2009, Pages 1498-1503

  Awais, D ^a,c   Siegel, C A ^a   Higgins, P D R ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b SPC 5682 ^*  (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; COLON RESECTION; COLORECTAL CANCER; GASTROINTESTINAL DYSPLASIA; GASTROINTESTINAL ENDOSCOPY; HUMAN; HUMAN TISSUE; MATHEMATICAL MODEL; METHODOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

BIOPSY; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; HUMANS; INTESTINAL MUCOSA; MODELS, THEORETICAL; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 70350227165     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.169714     Document Type: Article

References (27)

1. Eaden JA, Abrams KR, Mayberry JF, et al. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535 (Pubitemid 32234798)
2. Itzkowitz SH, Present DH, Crohn's and Colitis Foundation of America Colon Cancer in IBDSG, et al. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314-321
3. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology, et al. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-1385
4. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003;124:544-560 (Pubitemid 36169269)
5. Bernstein CN, Shanahan F, Weinstein WM, et al. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? [see comment]. Lancet 1994;343:71-74
6. Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Therap 2007;25:657-668 (Pubitemid 46272513)
7. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. [see comment]. Gastroenterology 2003;125:1311-1319
8. Ullman TA, Loftus EV Jr, Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis.[see comment]. Am J Gastroenterol 2002;97:922-927 (Pubitemid 34408249)
9. Kiesslich R, Neurath MF, Kiesslich R, et al. Chromoendoscopy and other novel imaging techniques. Gastroenterol Clin N Am 2006;35:605-619 (Pubitemid 44307576)
10. Hurlstone DP, Sanders DS, Lobo AJ, et al. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation.[see comment]. Endoscopy 2005;37:1186-1192
11. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.[see comment]. Gastroenterology 2003;124:880-888
12. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis.[see comment]. Gut 2004;53:256-260
13. Hurlstone DP, McAlindon ME, Sanders DS, et al. Further validation of highmagnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2004;126:376-378
14. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103:1611-1620
15. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance.[see comment]. Gastrointestinal Endoscopy 2000;51:123-128
16. Sadahiro S, Ohmura T, Yamada Y, et al. Analysis of length and surface area of each segment of the large intestine according to age, sex and physique. Surg Radiolog Anat 1992;14:251-257
17. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. Jama 1983;249:1743-1745
18. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-413
19. Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006:CD000279.
20. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561-7; quiz 818-819
21. Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 2007;65:998-1004.
22. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004;60:334-339 (Pubitemid 39164238)
23. Velayos F, Terdiman JP, Liu L, et al. Probability of occult cancer in ulcerative colitis with dysplasia: a modern assessment. Gastroenterology 2007;132:A-67, Abstract 389.
24. Siegel CA, Schwartz LM, Woloshin S, et al. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Gastroenterology 2008;134:A-346, Abstract M1135.
25. Amling CL, Amling CL. Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening? Curr Treat Options Oncol 2006;7:337-345
26. Benoit RM, Naslund MJ, Benoit RM, et al. The socioeconomic implications of prostate-specific antigen screening. Urol Clin N Am 1997;24:451-458 (Pubitemid 27169270)
27. Hernandez J, Thompson IM, Hernandez J, et al. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004;101:894-904. (Pubitemid 39100420)